| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director
1 company
James W. Newman Jr. last filed a Form 4 in May 2025, as Director at ADIL. James W. Newman Jr.'s net worth is not public. Form 4 filings only show shares in the companies where this person was an insider, as of the last filing.
At the last filing, the largest reported position was 34,644 shares of ADIL. Net of sales, the ADIL filings show accumulation of 74,644 shares.
James W. Newman Jr. has 12 Form 4 filings on record from July 2018 to May 2025, all as Director at Adial Pharmaceuticals (ADIL), 2018–2025.
The 37 reported transactions were 15 other transactions, 11 open-market purchases, 6 option or other derivative awards and 3 conversions, plus smaller numbers of other types.
Counted by filing, the open-market trades come to 3 purchases worth about $123K and no sales.
The largest open-market purchase was 25,000 shares of ADIL at an average $2.69 on December 30, 2021, about $67K. Twelve months later ADIL was down 92%.
Shares as reported in the last Form 4 for each company; the most recent is from May 2025. Values use today's prices. Any trades after the last filing were not reported, so current holdings may differ.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Dec 30, 2021 | ADIL Adial Pharmaceuticals, Inc. | Director | Buy | 25,000 | $2.69 | $67,300.00 | +259.2% | -25.1% | -91.9% | |
| Nov 26, 2021 | ADIL Adial Pharmaceuticals, Inc. | Director | Buy | 10,000 | $2.85 | $28,500.00 | +40.9% | -23.5% | -90.2% | |
| Mar 27, 2020 | ADIL Adial Pharmaceuticals, Inc. | Director | Buy | 19,644 | $1.36 | $26,769.40 | -392.9% | - | - | |
| Jul 31, 2018 | ADIL Adial Pharmaceuticals, Inc. | Director | Buy | 20,000 | $0.00 | - | -200.0% | - | - |